Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports

March 14th 2023

Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

March 7th 2023

CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

February 28th 2023

Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

February 10th 2023

Petra Capital - Immutep - The stage is set for an explosive 2023; Reit Buy & lift TP by 8% to A$1.30 (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

January 31st 2023

Ladenburg Thalmann - One Asset and Multiple Opportunities; Reit Buy and $8.30 Target (Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor

December 14th 2022

Bell Potter - Analyst Outlook & Stock Picks for 2023

December 7th 2022

Wilsons - Healthcare in 2023: Our Top Six

December 6th 2022

Bell Potter - Immutep (IMM): Manufacturing process established for IMP761 (autoimmune disease targeting antibody) (Analyst: Dr Tara Speranza)

For a copy of this analyst report please contact your Bell Potter advisor.

December 5th 2022

Jefferies - Immutep (IMM AU, BUY): Expanding into Urothelial Cancer (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor

November 29th 2022

CLSA Equity Research - Immutep (IMM) announces a new collaboration with Merck KGaA and Pfizer for a Ph 1 clinical trials for metastatic urothelial cancer (INSIGHT-005) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

November 29th 2022

Petra Capital - Immutep Limited (IMM) - New clinical trial collaboration with Merck KGaA/Pfizer for Phase 1 with efti in urothelial cancer, a positive with more to come (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

November 29th 2022

Wilsons Equity Research - Immutep Limited (IMM) | Keytruda isn’t the only kid in the Efti sandbox (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 16th 2022

Petra Capital - Immutep Limited (IMM) - Stellar NSCLC showing at SITC, registrational trial in 2H23 (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

November 13th 2022

goetzpartners securities Research - Immutep Limited (IMM-AU): Efti lung benefits better longer versus standard of care

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

November 11th 2022

Ladenburg Thalmann - SITC: Efti Is Active in NSCLC, Adaptive Registration Trial Is Next; Reaffirm Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor

November 11th 2022

CLSA Equity Research - Unrealised value - Lung data update supportive of overall value realisation into CY23 (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

November 11th 2022

Wilsons Equity Research - Immutep Limited (IMM) | A registrational trial within 12 months! (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 10th 2022

Jefferies - IMM AU Releases Positive SITC Data (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor

November 10th 2022

Maxim Group - Efti in 1L Lung Cancer at SITC – Response Rates are Favorable, but it's the Duration of Response that Impresses (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

November 8th 2022

Wilsons Equity Research - Immutep Limited (IMM) | Durable responses in 1L NSCLC with Efti (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 7th 2022

Maxim Group - Late-Breaking Abstract for Eftilagimod Selected for SITC Press Conference (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

October 26th 2022

Ladenburg Thalmann - NSCLC Is the Focus for Late-stage Development; Reiterate Buy and $8.30 PT (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

October 25th 2022

Petra Capital - Immutep Limited (IMM) - TACTIcal IO Positioning - Hard to Ignore; Initiating with Buy rating and A$1.19 Target (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor.

October 9th 2022

goetzpartners securities Research - Immutep Limited (IMM-AU): FDA fast-tracks efti as chemo alternative in NSCLC

October 6th 2022

CLSA Equity Research - PD-L1 competition good for efti - GSK’s PD-L1 result highlights increasing competition for Keytruda (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

October 5th 2022

Maxim Group - Looking Towards SITC In November; Eftilagimod Abstracts Accepted (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

October 4th 2022

CLSA Equity Research - Tracking positively - FDA NSCLC Fast Track designation follows promising data readout (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

October 4th 2022

Wilsons Equity Research - Immutep Limited (IMM) | FastTrack for Efti in 1st line NSCLC (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 15th 2022

goetzpartners securities Research - Immutep Limited (IMM-AU): Boosting checkpoint utility in lung and other solid cancers

September 5th 2022

CLSA Equity Research - Immutep : On to the main acts (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

August 31st 2022

CLSA Equity Research - Immutep FY22 Result: Cash runway to early-CY24; may prioritise 1L NSCLC trial (which is in combo with Keytruda) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

August 31st 2022

Jefferies - Immutep Ltd | BUY : IMM AU | AUD0.29 | PT: AUD1.00 (AUD0.90) | % to PT: +245% - FY22: Run (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor

August 2nd 2022

Maxim Group - Interim Data from TACTI-002 Study to be Presented at World Conference on Lung Cancer, Aug 6-9 (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

August 1st 2022

Wilsons Equity Research - Chemo-free efficacy – yes please! (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

August 1st 2022

Ladenburg Thalmann - One Drug, Multiple Late-stage Opportunities; Reiterate Buy Rating (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

July 22nd 2022

Jefferies - IMM AU - Increased Importance of TACTI-003 for MRK in HNSCC (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

June 29th 2022

goetzpartners securities Research - Efti-PD-X synergy opens >$6bn NSCLC opportunity

June 7th 2022

CLSA Equity Research - Not Lag-ging - Ph2 data support progression to Ph3 on positive results (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

June 7th 2022

Bell Potter - IMM - a very viable big pharma target (Analyst: Dr Tara Speranza)

June 6th 2022

Maxim Group - Positive 1L Lung Cancer Data for Efti/Pembro at ASCO; Webcast Today at 6pm ET (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

June 6th 2022

Wilsons Equity Research - ASCO data lays the path to Phase III (Analysts: Dr Melissa Benson and Dr Shane Storey)

June 4th 2022

Jefferies - IMM AU releases ASCO Data (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

May 27th 2022

CLSA Equity Research - Another promising readout - 1L NSCLC readout shows slight increase in ORR in larger patient cohort (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

May 27th 2022

Wilsons Equity Research - Immutep Limited (IMM) | Efti continues to win in NSCLC (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 12th 2022

Maxim Group - Disappointing Data for TIGIT; Nice Set up for Immutep’s soluble LAG-3 in 1L NSCLC? ASCO is Next (Analyst: Dr Naureen Quibria)

For a copy of this analyst report please contact your Maxim advisor John Law - jlaw@maximgrp.com or biotech analyst Naureen Quibria - nquibria@maximgrp.com

May 5th 2022

CLSA Equity Research - Raising the profile - AIPAC data continues to support MOA ahead of key conference (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

May 5th 2022

Bell Potter - Breast cancer trial data supports mechanism of action (Analyst: Dr Tara Speranza)

April 29th 2022

Wilsons Equity Research - Immutep Limited (IMM) | A coveted ASCO spot for Efti (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 25th 2022

Ladenburg Thalmann - ELCC Abstract: First Data in 2L NSCLC from TACTI-002; Reiterate Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

March 24th 2022

Jefferies - New TACTI-002 Data - Efficacy in Line, SE Lower (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

March 24th 2022

Wilsons Equity Research - Immutep Limited (IMM) | IO non-responder patients saved by Efti (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 24th 2022

CLSA Equity Research - Keep on keeping on - 2L NSCLC within expectations, but 1L HNSCC & NSCLC remain focus (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

March 21st 2022

Ladenburg Thalmann - The Key Approval Arrived in the LAG-3 Arena (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

March 20th 2022

CLSA Equity Research - LAG-3 launch pad - FDA approval of LAG-3 therapy a key milestone for the sector (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

March 19th 2022

Jefferies - First LAG-3 Checkpoint Inhibitor Approved (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

March 1st 2022

CLSA Equity Research - Hitchin’ a ride - BMS’ LAG-3 FDA approval could see increased interest in I-O sector (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

February 23rd 2022

Maxim Group - Reports Half-Year Results; Eyeing the First External LAG-3 Approval from Bristol (Analyst: Dr Naureen Quibria)

For a copy of this Analyst report please contact your Maxim advisor John Law - jlaw@maximgrp.com or biotech analyst Naureen Quibria - nquibria@maximgrp.com

February 4th 2022

Alliance Global Partners - Indications Come and Go, But Immutep's Development of Efti Is About LAG-3 Itself

January 31st 2022

Ladenburg Thalmann - Our Top Picks for 2022 (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

Ladenburg has selected Immutep as one of its top 3 biotech stock picks for 2022. For a copy of this research report please contact your Ladenburg advisor.

December 14th 2021

Wilsons Conviction Insights Report - December 2021 - Immutep is a top biotech pick (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

December 7th 2021

Wilsons Equity Research - Healthcare in 2022: The Top Six (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

Wilsons has included Immutep as one of its top six healthcare stocks for 2022.

December 1st 2021

Jefferies - Turning Cold Cancers Hot – Initiating at Buy - TP to $A1 (ASX: IMM) (Analyst: Dr Dave Stanton)

For a copy of this Analyst report please contact your Jefferies advisor.

November 23rd 2021

Taylor Collison - AIPAC disappoints but TACTI-003 adding value - Increasing TP to $A1.36 (from $A1.19) (ASX: IMM) (Analyst: Dr Dennis Hulme)

For a copy of this Analyst report please contact your Taylor Collison advisor.

November 22nd 2021

goetzpartners securities -Data highlights efti efficacy and potential central role in cancer therapy - Reiterate OUTPERFORM and TP of AUD 1.350

November 18th 2021

Wilsons Equity Research - Immutep Limited (IMM) | Efti impresses in HNSCC and aids the young & forgotten in metastatic breast cancer (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 17th 2021

Maxim Group - AIPAC Presentation at SITC Builds on Prior Data, Prepping to Go Pivotal in mBC

November 10th 2021

CLSA Equity Research - Not worth less today than yesterday - Increasing TP to A$1.33 (from A$1.19) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

November 10th 2021

Wilsons Equity Research - AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 4th 2021

Wilsons Equity Research - O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

October 16th 2021

CLSA Equity Research - On the right pathway - Initiating coverage with a Buy Rating of A$1.19 TP (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

October 13th 2021

Corporate Connect - A Truly Undervalued Company – Target Price of A$2.20 (ASX:IMM) (Analyst: Marc Sinatra)

September 21st 2021

Maxim Group - The Case for LAG-3 is Building

August 31st 2021

Maxim Group - Annual FY Update; AIPAC Final Data Approaching

August 3rd 2021

Ladenburg Thalmann - New Age Immune Regulator - Initiate with a Buy Rating of US$8.30 TP (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

July 16th 2021

Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 TP

July 14th 2021

Bell Potter - Creating Value with Phase 3 around the corner – Increasing TP to AUD 1.00 (from AUD 0.85)

July 7th 2021

goetzpartners securities -LAG-3 therapies taking immunology to the next level - Increasing TP to AUD 1.35 (from AUD 1.24)

July 6th 2021

Taylor Collison - Efti development program expanded - Increasing TP to AUD 1.19 (from AUD 0.85)

For a copy of this research report please contact your Taylor Collison advisor.

June 10th 2021

Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 Immunotherapy — increasing to US$9 (from US$6)

June 5th 2021

goetzpartners securities - Efti combos move towards centre stage at ASCO : Increasing TP to A$1.24 (from A$0.90)

June 5th 2021

Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares Remain Undervalued

May 21st 2021

goetzpartners securities - BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma

May 3rd 2021

Corporate Connect - Efti a highly sought after compound for mono & combo Cancer treatment

April 9th 2021

Bell Potter - Efti granted Fast Track - A vote of confidence (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

April 8th 2021

Alliance Global Partners - FDA's Fast Track for Efti Suggests Regulators Echo Large Pharma Enthusiasm Surrounding LAG-3 Immunotherapy

March 31st 2021

Bell Potter - Validation for LAG-3 arrives (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

March 25th 2021

goetzpartners securities - BMS Study Identifies LAG-3 - PD-1 as Potential 'Key Strategy'

March 25th 2021

Maxim Group - Bristol Brings LAG-3 to the Forefront in Checkpoints with First Positive P3 Trial; Bodes Well for Efti and LAG-3 Pipeline

March 17th 2021

goetzpartners securities - Targeting first-line head and neck with Merck & Co

March 16th 2021

Maxim Group - Success in 2L H&N Cancer Leads to Second Collaboration to Move into 1L – Reiterate Buy

March 6th 2021

Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 25th 2021

Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 5th 2021

Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

January 26th 2021

Alliance Global Partners - Raising PT to $6 from $5; MBC Program Thrown a Lifeline by OS Data as IMMP Shares Find Their Heading for the Year of the Sea Shanty

December 15th 2020

goetzpartners securities - Door re-opens to first eftilagimod alpha approval

December 11th 2020

Maxim - Efti Was Out in Breast Cancer...Or Was it? Update from Ongoing SABCS meeting, Raising PT to $8

November 19th 2020

Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete

November 11th 2020

Maxim - The Data for Efti in Lung and H&N Continues to Build – Raising PT to $4, from $2

November 11th 2020

goetzpartners securities - Striking support for efti - checkpoint inhibitor combos

November 4th 2020

Maxim - TACTI-002 Data (efti + pembro) to be Presented at SITC Meeting; Late Breaker Poster

October 27th 2020

Bell Potter - Efti now tackling COVID-19 (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

September 23rd 2020

Alliance Global Partners - Eclipsing the LAG-3 Laggards in the Running for the Next Breakthrough in Immunotherapy

September 18th 2020

Taylor Collison - Immutep (IMM) Further positive efti data at ESMO

September 17th 2020

Bell Potter - Underappreciated immunotherapy player with leadership in LAG-3 (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

August 26th 2020

Taylor Collison - BMS/Dragonfly deal drives valuation upgrade

June 3rd 2020

goetzpartners securities - ASCO data underscores efti-PD-1 / L1 synergy

June 3rd 2020

Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

June 2nd 2020

JonesTrading - Responses to Efti + Pembro are Deepening Over Time, as is the Combo’s Market Opportunity with ASCO Data Positing Promise in New Indications

May 14th 2020

goetzpartners securities - First in class opening the cancer immune throttle

April 30th 2020

Maxim - Data From TACTI-002 Continues to be Positive, Activity In the Space Bodes Well for Immutep

April 22nd 2020

Taylor Collison - Immutep (IMM) Leading not LAGging

March 27th 2020

Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

March 27th 2020

JonesTrading - AIPAC Setback Leaves a Mark on Efti’s Otherwise Impeccable Clinical Report Card, but Don’t Warrant a Failing Grade for Immutep

March 26th 2020

goetzpartners securities - Efti breast trial: Down certainly not out

February 24th 2020

JonesTrading - Efti + Pembro Value Proposition in NSCLC is Crystallizing as TACTI-002 Suggests Combo is Competitively Effective and Far More Tolerable

February 20th 2020

Maxim - Valuation is Rising as First of 2 Key Catalysts Delivers (TACTI-002 in Lung Cancer, H&N); Breast Cancer P2b is Next (CY1Q20)

February 20th 2020

goetzpartners securities - Efti-pembro combo: A new option in NSCLC?

February 18th 2020

Bell Potter - Global leader in LAG-3, the hottest emerging immune checkpoint (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

January 30th 2020

Maxim - Inflection Points Approaching- Lung Cancer Data (February), Breast Cancer Data (March)

January 11th 2020

Maxim - TACTI-002 Head & Neck Cancer Study is Expanding, Data Updates Over 2020 – Reiterate Buy

October 28th 2019

Maxim - Runway Through CY20, Upcoming Catalysts ShouldContinue to Drive a Higher Valuation

October 16th 2019

goetzpartners securities - TACTI-mel final data confirm efficacy signals

September 27th 2019

goetzpartners securities - Positive interim analysis for TACTI-002

September 23rd 2019

Maxim - GSK Initiates New Trial for IMP731-Derived Therapy, Triggers Milestone to Immutep

September 23rd 2019

goetzpartners securities - Unlockgoetzpartners securities - £4M from GSK extend cash runway to YE2020E

July 2nd 2019

Edison - AIPAC fully recruited, results due Q120

May 1st 2019

Maxim - Immutep Provides Corporate Update, Data Points Ahead in 2019

April 24th 2019

goetzpartners securities - Unlocking the value of LAG-3 in autoimmunity

April 9th 2019

Edison - Encouraging results for efti and IMP761

March 27th 2019

LifeSci Capital - Immutep Ltd (IMMP) Positive Signals in Pre-Clinical Studies with IMP761

March 9th 2019

Maxim - Checkpoints on the Flipside of Immune Oncology... Autoimmune disease - Immutep’s LAG-3 IMP761 Highlighted at ECCO

March 7th 2019

Maxim - Advancing the Second Merck Collaboration, TACTI-002 Doses First Patient

March 6th 2019

LifeSci Capital - Immutep Ltd (IMMP) Presents Updated Data from Ongoing TACTI-Mel Study

February 28th 2019

Maxim - Half Year Update: Expecting Data Updates from the LAG3Pipeline in 2019

February 5th 2019

goetzpartners securities - 2019 a decisive year rich in news flow

February 1st 2019

Maxim - Provides Update- Catalysts Ahead in 2019 in Several Programs around LAG-3

November 28th 2018

Maxim - More TACTI-mel Data Presented at the Annual ICI Europe Summit

November 21st 2018

Edison - A big year ahead for efti

November 13th 2018

Maxim – Immutep Presents “efti” (LAG-3) Data at SITC Summary

November 2nd 2018

goetzpartners securities - Pipeline on track at operational update

October 31st 2018

Maxim – Pipeline Update: Catalysts Ahead in the LAG-3 Franchise

October 18th 2018

LifeSci Capital Initiates Coverage of Immutep (IMMP)

September 28th 2018

B Riley FBR - Leading the LAG-3 Immunotherapy Charge into Immuno-oncology and Autoimmune Disease – Initiating Coverage

September 27th 2018

goetzpartners securities - Key takeaways from investor meetings in London

September 27th 2018

Edison - Merck /Pfizer collaboration - A second big pharma collaboration for efti

September 25th 2018

Maxim - GSK, Novartis, Merck... Now Merck KGAA and Pfizer... Pharma Collaborations Expand for LAG-3 Pipeline

August 31st 2018

Edison Research - LAG-3 Progress In-House and Via Partner

August 8th 2018

Maxim – Pipeline Update: Eftilagimod Moves Forward, Partners are Busy - Novartis, GSK, EOC (China)

July 31st 2018

Maxim – First US-Based Study of IMP321 Gets Green Light from FDA, Initiating 2H18

July 30th 2018

Maxim – Reports June Quarter: Cash Runway Through Several Data Points in the LAG-3 Pipeline

July 28th 2018

Maxim – Update on the LAG-3 Landscape; Immutep's Partners are Busy

July 12th 2018

goetzpartners securities - Targeting the LAG-3 immune checkpoint

July 3rd 2018

Maxim - First IND Filed in US for IMP321 (eftilagimod), Phase 2 Study with Keytruda 2H18

June 4th 2018

Partner Novartis Presents Early Efficacy Signal Data for LAG525 + PD1

May 25th 2018

IMP321 + Keytruda Data Continues to be Positive in Melanoma, ASCO Next - Raising Price Target to $7

March 29th 2018

Merck collaboration opens new opportunities

March 23rd 2018

IMP321 (LAG-3Ig) + Keytruda in Melanoma - Expansion Cohort Initiates Dosing

March 16th 2018

Maxim - Raises Capital ($5.4M), Extends Runway as IMP321 Expands to a New Combination Study with Keytruda

February 18th 2018

Maxim - Lowering Price Target to $5

February 2nd 2018

Maxim - LAG-3; The Next Emerging Checkpoint in Immune Oncology

December 13th 2017

EDISON - Encouraging LAG-3 combo data at SITC

November 29th 2017

Maxim - IMP321 + Keytruda: Positive Data in Melanoma to be Presented at SITC

November 16th 2017

Maxim - IMP321 (LAG-3Ig) Heating up the T cell Response for Keytruda in Melanoma - New Data To Be Presented at-SITC

October 11th 2017

Edison - Support for anti-LAG-3 and APC-activator combos

September 7th 2017

Edison - Support for Anti-Lag-3 and APC-Activators Combos

August 2nd 2017

Maxim Research - Understanding LAG-3 Function in Controlling T Cells- Grant Funding Awarded to Prima

July 2nd 2017

Maxim PBMD Report - Coming to the Next Checkpoint: LAG-3 and Prima has the Right Partner in Novartis

June 2nd 2017

Edison - Preliminary LAG-3 combo data in breast cancer

March 2nd 2017

Edison - Initial LAG-3 combo data presented

February 2nd 2017

H.C. Wainwright - Looking Ahead to a Catalyst-Rich 2017; Reiterate Buy

February 2nd 2017

Edison - Prima BioMed - AIPAC Phase IIb starts randomized component

January 2nd 2017

FRB & Co. - Green Shoots from Broad Clinical Progress Are Emerging

January 2nd 2017

Research Note – Ongoing strong data support LAG-3 pipeline

December 31st 2016

Maxim Group - LAG-3 + Keytruda: Safe So Far - Moving to Higher Dose; Adjusting Model for New ADR Ratio and Reducing Price Target

November 24th 2016